Department of Radiology, Lanzhou University Second Hospital, Lanzhou, Gansu, China.
Second Clinical School, Lanzhou University, Lanzhou, Gansu, China.
J Magn Reson Imaging. 2022 Aug;56(2):325-340. doi: 10.1002/jmri.28103. Epub 2022 Feb 7.
In recent years, the development of advanced magnetic resonance imaging (MRI) technology and machine learning (ML) have created new tools for evaluating treatment response and prognosis of patients with high-grade gliomas (HGG); however, patient prognosis has not improved significantly. This is mainly due to the heterogeneity between and within HGG tumors, resulting in standard treatment methods not benefitting all patients. Moreover, the survival of patients with HGG is not only related to tumor cells, but also to noncancer cells in the tumor microenvironment (TME). Therefore, during preoperative diagnosis and follow-up treatment of patients with HGG, noninvasive imaging markers are needed to characterize intratumoral heterogeneity, and then to evaluate treatment response and predict prognosis, timeously adjust treatment strategies, and achieve individualized diagnosis and treatment. In this review, we summarize the research progress of conventional MRI, advanced MRI technology, and ML in evaluation of treatment response and prognosis of patients with HGG. We further discuss the significance of the TME in the prognosis of HGG patients, associate imaging features with the TME, indirectly reflecting the heterogeneity within the tumor, and shifting treatment strategies from tumor cells alone to systemic therapy of the TME, which may be a major development direction in the future. LEVEL OF EVIDENCE: 5 TECHNICAL EFFICACY STAGE: 4.
近年来,先进的磁共振成像(MRI)技术和机器学习(ML)的发展为评估高级别胶质瘤(HGG)患者的治疗反应和预后提供了新的工具;然而,患者的预后并没有显著改善。这主要是由于 HGG 肿瘤之间和内部的异质性,导致标准治疗方法不能使所有患者受益。此外,HGG 患者的生存不仅与肿瘤细胞有关,还与肿瘤微环境(TME)中的非癌细胞有关。因此,在 HGG 患者术前诊断和随访治疗中,需要非侵入性成像标志物来描述肿瘤内异质性,然后评估治疗反应和预测预后,及时调整治疗策略,实现个体化诊断和治疗。在这篇综述中,我们总结了常规 MRI、先进 MRI 技术和 ML 在评估 HGG 患者治疗反应和预后中的研究进展。我们进一步讨论了 TME 在 HGG 患者预后中的意义,将影像学特征与 TME 相关联,间接反映肿瘤内部的异质性,并将治疗策略从单独针对肿瘤细胞转变为针对 TME 的系统性治疗,这可能是未来的一个主要发展方向。证据水平:5 技术功效阶段:4